No Data
No Data
Bluebird Bio Announces Second Quarter 2024 Results Call Date
BofA Upgrades Editas to Buy, Cites Reni-cel Progress
Express News | Bluebird bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Bluebird Network Welcomes Travis Noble as Chief Revenue Officer
Actinium Wins FDA Nod to Conduct Clinical Trial for Radiotherapy
BofA Securities Maintains Bluebird Bio(BLUE.US) With Buy Rating
No Data
thedioyears : What price? and how many?
ETONA OP : 1.25
not much hehe
now waiting for the dip
thedioyears ETONA OP : Not bad lol you'll be able to buy back in lol. Seen this too many times
70205719 : buy more, still lower price.